Skip to content
10-Q

Quarterly Report

KALEIDO BIOSCIENCES, INC.

0001564590-21-022992

← back to feed
Filed
May 4, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Apr 30, 2021 42.52M sh
Capex Q1 2021 · Mar 31, 2021 $30K
Capex Q1 2021 · Mar 31, 2020 $1.08M
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$23.97M
Operating Cash Flow Q1 2021 · Mar 31, 2020 −$17.9M
Long Term Debt Q1 2021 · Mar 31, 2021 $16.43M
Long Term Debt Q1 2021 · Dec 31, 2020 $18.38M
Short Term Debt Q1 2021 · Mar 31, 2021 $4.76M
Short Term Debt Q1 2021 · Dec 31, 2020 $2.63M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $92.36M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $46.22M
Stockholders Equity Q1 2021 · Mar 31, 2021 $71.77M
Stockholders Equity Q1 2021 · Dec 31, 2020 $20.5M
Stockholders Equity Q1 2021 · Mar 31, 2020 $33.62M
Stockholders Equity Q1 2021 · Dec 31, 2019 $48.88M
Current Liabilities Q1 2021 · Mar 31, 2021 $12.87M
Current Liabilities Q1 2021 · Dec 31, 2020 $16.66M
Total Liabilities Q1 2021 · Mar 31, 2021 $33.25M
Total Liabilities Q1 2021 · Dec 31, 2020 $38.85M
Current Assets Q1 2021 · Mar 31, 2021 $95.03M
Current Assets Q1 2021 · Dec 31, 2020 $48.72M
Total Assets Q1 2021 · Mar 31, 2021 $105.03M
Total Assets Q1 2021 · Dec 31, 2020 $59.34M
Sga Expense Q1 2021 · Mar 31, 2021 $5.46M
Sga Expense Q1 2021 · Mar 31, 2020 $5.92M
Rd Expense Q1 2021 · Mar 31, 2021 $17.19M
Rd Expense Q1 2021 · Mar 31, 2020 $13.14M
Net Income Q1 2021 · Mar 31, 2021 −$23.04M
Net Income Q1 2021 · Mar 31, 2020 −$19.55M
Operating Income Q1 2021 · Mar 31, 2021 −$22.35M
Operating Income Q1 2021 · Mar 31, 2020 −$19.05M
Revenue Q1 2021 · Mar 31, 2021 $297K